Leadership & People
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Recent executive moves in the industry include changes at the top at Spyre Therapeutics, Neopharmed Gentili and CytoDyn.
The company said during its R&D day that it has culled its pipeline to 103 clinical stage assets, choosing to focus on drugs that could be big blockbusters.
In an interview with Scrip, Astellas’s India chief outlines how the Japanese company expects to build out its operations in the country, with a flurry of key launches in the wings. She also shares vignettes of her own career path, which has not been a bed of roses.
In accepting Scrip’s Lifetime Achievement Award, Ovid Therapeutics’ CEO called on pharma to show responsible leadership and live up to its potential to do good for society.
Recent moves in the industry include internal rejigs at Homology Medicines, Virpax Pharmaceuticals, CytoDyn and Applied Therapeutics, plus new board members at Neuroscientific Biopharmaceuticals.
Executives On The Move: New C-Suite Changes At Amneal Pharmaceuticals, Lexicon Pharmaceuticals And Amicus Therapeutics
Recent moves in the industry include changes at the top at Amneal Pharmaceuticals, plus new CEOs at Incendia Therapeutics and Nereid Therapeutics.
CEO Michael Engsig tells Scrip that his well-capitalized company has ambitious plans for US expansion and is looking to set up an autoimmune diseases arm to add to its oncology efforts.
The Swiss major’s business development chief Susanne Kreutz tells Scrip that geography is no barrier for her team in the search for promising licensing deals or bolt-on acquisitions.
Recent executive moves in the industry include changes at the C-suite at Astellas Pharma, plus new CEOs at Y-mAbs Therapeutics, Ocuphire Pharma and Neopharmed Gentili.
R&D leaders from Novo Nordisk, Lilly, Boehringer Ingelheim and others discussed what some of the advances could be in the next generation of obesity medicines.
Genentech CEO Alexander Hardy will succeed Jean-Jacques Bienaimé, who has led the rare disease specialist for 18 years. Gene therapy Roctavian has gotten off to a slow commercial start.
Recent executive moves in the industry include new CEOs at Viridian Therapeutic, Opthea and Gyre Therapeutics, while Bristol Myers Squibb confirms its new leadership.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.